

1 **From Vaccine to Pathogen: Modeling Sabin 2 Vaccine Virus Reversion and Evolutionary Epidemiology**

2 Wesley Wong^{1*}, Jillian Gauld^{1*}, Michael Famulare^{1*}

3

4 **Author Affiliations**

5 1. Institute for Disease Modeling, Global Good, Intellectual Ventures, Bellevue, WA, USA

6 * Currently employed at the Bill and Melinda Gates Foundation

7

8 **Corresponding Author**

9 Michael Famulare

10 Building IV, 3150 139th Ave SE, Bellevue, WA 98005

11 +1 (425) 691-3327

12 mfamulare@idmod.org

13

14 **Keywords:**

15 Sabin 2, cVDPV2, poliovirus, genetic reversion, evolution, modeling, vaccine

16 **Classification:** BIOLOGICAL SCIENCES: Evolution

17 **Author Contributions**

18 WW and MF were involved with model development, analysis, and interpretation. All authors were
19 involved with manuscript writing and interpretation. Correspondence and requests for materials should be
20 addressed to Michael Famulare.

21

22

23 **Abstract**

24 The oral poliovirus vaccines (OPV) are one of most effective disease eradication tools in public
25 health. However, the Sabin 2 vaccine strain can revert attenuation and cause outbreaks of circulating,
26 vaccine-derived poliovirus (cVDPV2) that are clinically indistinguishable from wild poliovirus (WPV).
27 Accurately assessing cVDP2 risk requires disentangling the complex interaction between epidemiology
28 and evolutionary biology. Here, we developed a Sabin 2 reversion model that simulates the reversion of
29 Sabin 2 to WPV based on the clinical differences in shedding duration and infectiousness between
30 individuals vaccinated with Sabin 2 and those infected with wild poliovirus. Genetic reversion is
31 informed by a canonical reversion pathway defined by three gatekeeper mutations (A481G, U2909C,
32 and U398C) and the accumulation of genetic load from deleterious nonsynonymous mutations. Our
33 model captures essential aspects of both phenotypic and molecular evolution and simulates
34 transmission using a multiscale transmission model that consolidates the relationships among immunity,
35 susceptibility, and transmission risk. We show that despite the rapid reversion of Sabin 2, cVDPV2
36 outbreaks can be controlled by maintaining high levels of population-level immunity and sanitation.
37 Supplementary immunization activities must maintain high vaccine coverage to prevent future cVDPV2
38 outbreaks in the targeted intervention zone, but declining global immunity against Sabin 2 makes them
39 increasingly risky to implement in poor sanitation regions regardless of historical immunization activity.
40 A combined strategy of assessing and improving sanitation levels in conjunction with high coverage
41 vaccination campaigns will limit future cVDPV2 emergence and spread.

42

43 **Significance Statement**

44 Since the withdrawal of the Sabin 2 oral poliovirus vaccine (OPV2), circulating vaccine-derived
45 poliovirus outbreaks caused by the genetic reversion of Sabin 2 vaccine virus (cVDPV2) have been

46 increasing in frequency. The current strategies for combating cVDPV2 involve supplemental
47 immunization activities with monovalent Sabin 2 oral poliovirus (mOPV2), which can inadvertently seed
48 future cVDPV2 outbreaks. Accurately assessing future cVDPV2 outbreak risk following mass mOPV2
49 campaigns is critical poliovirus eradication efforts but must consider the interaction between genetic
50 reversion and epidemiological transmission. We developed an evolutionary epidemiology model to
51 integrate Sabin 2 genetic reversion and transmission into a single framework to evaluate their relative
52 contribution to cVDPV2 outbreaks and inform future intervention strategies.

53

54 **Introduction**

55 Mass immunization with oral poliovirus vaccine (OPV) has led to a >99.99% drop in wild
56 poliovirus (WPV) cases (1) and the complete eradication of Type 2 and Type 3 WPV. The OPVs are highly
57 efficacious vaccines that confer long-lasting protective immunity (2). A curious feature of these vaccines
58 is that vaccinated individuals can shed and transmit vaccine virus. Vaccine transmission increases
59 population-level immunity but is problematic when viruses revert attenuation, resulting in circulating,
60 vaccine-derived poliovirus (cVDPV) capable of causing paralytic poliomyelitis cases clinically
61 indistinguishable from WPV (3). Following the eradication of Type 2 WPV, the Global Polio Eradication
62 Initiative coordinated the global withdrawal of Sabin 2 OPV (OPV2) from routine immunization
63 schedules (commonly referred to as the Switch) to prevent future sources of circulating, vaccine-derived
64 Type 2 poliovirus (cVDPV2) (1).

65 Despite the Switch, cVDPV2 outbreaks continue to be a pressing public health concern and have
66 emerged as a significant issue threatening global poliovirus eradication efforts (1, 4). Although OPV2 is
67 no longer used in routine immunization, monovalent OPV2 (mOPV2) vaccination campaigns are still
68 used as supplemental immunization activities (SIAs) to combat cVDPV2 outbreaks. cVDPV2 outbreaks

69 are now reported throughout the African continent, Pakistan, Afghanistan, China, Malaysia and the
70 Philippines and 29% of the outbreaks in Africa have involved international spread (4, 5). Since the
71 Switch, 126 mOPV2 campaigns utilizing more than 300 million doses of OPV2 have been implemented to
72 control cVDPV2 outbreaks (6). These SIAs are estimated to be responsible for seeding over half of the
73 cVDPV2 outbreaks observed since the Switch (6). Ensuring the future safety and efficacy of these SIA
74 campaigns while minimizing the risk of seeding future cVDPV2 outbreaks is critical to the success of the
75 poliovirus eradication initiative.

76 The Sabin 2 vaccine strain was derived from a wild-type isolate (P22/P712/56) passaged in
77 monkey kidney cells to achieve neurovirulence attenuation (7). However, identifying the genetic
78 mutations responsible for attenuation has been surprisingly complicated, in part because the progenitor
79 has not been fully sequenced and because P22/P712/56 is thought to be naturally attenuated relative to
80 other WPV strains (8). Despite this, phylogenetic analyses of whole genome sequences collected from
81 cVDPV2 outbreaks suggest a common evolutionary pathway to attenuation reversal (9). This pathway is
82 characterized by the rapid fixation three gatekeeper mutations, A481G, U2909C, and U398C, within the
83 first few weeks after vaccination (9, 10). All three mutations have previously been implicated as
84 molecular determinants of attenuation for Sabin 2 (11–14). A481G and U398C are noncoding mutations
85 that affect the stability of a 5' hairpin structure that mediates translation efficiency (13, 15, 16) and
86 U2909C is a nonsynonymous mutation in the VP1 capsid protein.

87 However, genetic reversion is not the sole determinant of cVDPV2 emergence. Environmental
88 sewer samples have identified revertant strains in regions with no detectable cVDPV2 cases (17). In fact,
89 vaccinated individuals can shed and transmit revertant viruses to other individuals (10, 18), but whether
90 this results in clinically-detected cVDPV2 outbreaks depends on the epidemiological context. These
91 cVDPV2 outbreaks are associated with regions with historically poor vaccination rates and low
92 population-level immunity (6, 19). Thus, while Sabin 2 reversion is a prerequisite of cVDPV2 emergence,

93 whether it triggers a public health crisis depends on the interactions between genetic reversion and
94 local epidemiological conditions.

95 Mathematical models can be useful tools for assessing cVDPV2 emergence risk and
96 characterizing the evolutionary and epidemiological factors that allow cVDPV2 outbreaks to occur. We
97 developed an evolutionary-epidemiology model that simulates Sabin 2 reversion as it is transmitted in
98 an epidemiological model previously calibrated during an mOPV2 clinical trial performed in Matlab,
99 Bangladesh (20). The combined model allows us to assess the consequences of vaccine reversion in the
100 context of an actual epidemiological setting. By unifying evolutionary theory, population genetics, and
101 epidemiology into a single framework, our study provides a holistic understanding of cVDPV2
102 emergence as it relates to both genetic reversion and transmission.

103

104 **Results**

105 *Brief model structure overview*

106 We previously developed agent-based multiscale epidemiology model designed to replicate
107 household community structure and Sabin 2 vaccine transmission during an mOPV2 clinical trial
108 performed in Matlab, Bangladesh (20, 21). Transmission is contact based and made heterogeneously
109 depending on household community structure membership (**Figure 1A**). Susceptibility is defined by a
110 dose-response model that determines the probability of infection given the strain-specific viral
111 infectiousness, the total viral exposure dose per contact, and the immunity of the recipient host. The
112 total viral exposure dose is determined by the viral shedding concentration of the infected individual
113 and the average fecal-oral dose per contact in the population. Immunity is defined by the OPV-
114 equivalent antibody titer that determines infection probability. Individuals with low immunity upon

115 infection have longer shedding durations and higher viral shedding titers. Further details of the
116 epidemiology model are described elsewhere (21, 22).

117 Here, we developed and integrated a new Sabin 2 reversion model into the multiscale
118 epidemiology model. Sabin 2 evolution is modeled as a population of multiple viral lineages founded by
119 a Sabin 2 vaccine virus strain during vaccination. These viral lineages evolve independently and compete
120 for the limited availability of naïve or low-immunity individuals in the population. Phenotypic evolution
121 is driven by the reversion of three gatekeeper mutations (A481G, U2909C, and U398C) and the
122 accumulation of deleterious nonsynonymous mutations generated through mutation and purged
123 through selection or genetic drift (**Figure 1B**). We assume complete genetic reversion results in a viral
124 population whose average infectiousness and shedding duration is identical to those of WPV. Due to the
125 independent acquisition of mutations across different viruses and viral lineages, individual viruses have
126 different infectiousness and shedding duration phenotypes even after the three gatekeeper mutations
127 have reverted.

128 *Simulating Sabin 2 molecular evolution*

129 To inform molecular evolution, intra-host substitution rates for the three gatekeeper mutations
130 were based on estimates previously calculated from 241 Vp1 (viral protein 1) segments from Sabin-like
131 poliovirus collected during routine surveillance in Nigeria (10, 23). Nonsynonymous and synonymous
132 substitution rates were calibrated (**SI Appendix**) to a set of whole genome sequences and VP1 capsids
133 segments isolated from infections from confirmed Sabin 2, Sabin-like, vaccine-derived poliovirus (VDPV)
134 and cVDPV2 cases (**Figure 2**). One notable feature of poliovirus evolution is the discordance between
135 short-term evolution following vaccination and long-term evolution after prolonged circulation. Short-
136 term evolution is dominated by the accumulation of nonsynonymous mutations, as evidenced by the
137 increased rate of nonsynonymous mutation accumulation in the whole genome sequences during the

138 first year of evolution (**Figure 2B**), the reduction in the ratio of nonsynonymous to synonymous
139 mutations over time (**Figure 2D**), and the elevated dN/dS ratios of Sabin-like samples compared to
140 cVDPV2 samples (**Supplemental Figure 1**).

141 We hypothesized that the difference between short-term and long-term evolution represents a
142 shift in the distribution of fitness effects for nonsynonymous mutations. Simulated nonsynonymous
143 mutations were divided into two categories: deleterious mutations that can cause a reduction in either
144 infectiousness or shedding duration, and neutral mutations that have no phenotypic effect. Each
145 category is associated with a different substitution rate and deleterious nonsynonymous mutations are
146 purged using a recombination-like process that mimics selection and intra-species recombination within
147 the host (**SI Appendix**). Deleterious nonsynonymous mutations dominate molecular evolution during the
148 first year of evolution while neutral nonsynonymous mutations dominate molecular evolution after
149 prolonged circulation (**Figure 2E**).

150 *Simulating Sabin 2 reversion*

151 Genotype-to-phenotype maps for shedding duration were generated by comparing the
152 shedding duration of naïve individuals vaccinated with Sabin 2 (median 30.3, average 36 days) with
153 those infected with WPV (median 40.3, average 48 days) (**SI Appendix**). Due to the rapid intra-host
154 fixation of the three gatekeeper mutations (**Figure 3A**), we assert that reversion during an infection
155 extends its shedding duration (**Figure 3B**). Prior to any intra-host evolution, the genotype-to-phenotype
156 map for shedding duration estimates that naïve individuals vaccinated with non-reverted Sabin 2 have a
157 median shedding duration of 13.5 days (**Figure 3B**, *dashed red line*). The clinically-observed shedding
158 durations of Sabin 2 vaccinated individuals (**Figure 3B**, *solid red line*) is realized as the average shedding
159 durations of different viral genotypes composed of unmutated and reverted Sabin 2 viruses
160 (**Supplemental Table 1**). After vaccination, 7.6% of simulated vaccinated individuals shed non-reverted

161 Sabin 2 at the end of shedding, 92.4% shed virus with at least one reverted gatekeeper mutation, and
162 35.2% shed virus with all three gatekeeper mutations reverted. Interestingly, we did not identify a
163 deleterious cost (reduction in shedding duration) associated with nonsynonymous mutation
164 accumulation (**SI Appendix**).

165 The genotype-to-phenotype map describing viral infectiousness was based on clinical
166 differences of human dose response between Sabin 2 and WPV. Unlike shedding duration, we identified
167 a small negative effect associated with deleterious nonsynonymous mutations resulting in a reduction in
168 viral infectiousness (**SI Appendix**). Our model predicts that viral genotypes with no deleterious
169 nonsynonymous mutations but are reverted at A481G and U2909C are more infectious than typical WPV
170 strains (**Figure 3C**). Each additional deleterious nonsynonymous mutation reduces infectiousness such
171 that a viral genotype with all three gatekeeper mutations reverted and nine deleterious mutations is as
172 infectious as WPV (**Figure 3D**).

173

174 *Examining the evolutionary epidemiology dynamics of Sabin 2 reversion*

175 To explore how Sabin 2 reversion and transmission interact, we simulated transmission
176 following an mOPV2 campaign targeting 10% of children under five in a population with 10 times the
177 fecal-oral dose of Matlab (2.5e-6 grams per contact) five years after vaccination cessation (**Figure 4**).
178 These epidemics are cyclic (**Figure 4A**) and characterized by boom-bust cycles that eventually stabilize
179 within the first three years of transmission. Under these conditions, 10% of stochastic replicates failed to
180 establish stable, endemic transmission. These stochastic replicates failed after the initial expansion wave
181 collapsed (**Supplemental Figure 2A**). Should transmission recover, the epidemic rebounds and the
182 proportion of individuals with no immunity (serum neutralizing antibody titer < 8) declines while the
183 proportion of individuals with high immunity (serum neutralizing antibody titer > 256) increases (**Figure**

184 **4B**). Towards the end of the initial epidemic, the proportion of individuals with no immunity begin to
185 increase due to a combination of new births and the waning of pre-existing immunity and sets up the
186 conditions for the next wave of infections.

187 Complete Sabin 2 reversion (**Figure 4C-D**) occurred within the first 200 days of transmission. To
188 describe the evolutionary dynamics of the simulated viral population, we focused on the expected mean
189 (the average of the average) phenotype and the variance of the expected mean. While both shedding
190 duration and infectiousness converged to the WPV phenotype, shedding duration approached it
191 monotonically while infectiousness exceeded WPV during the first few months of transmission. The
192 expected means of both phenotypes were not sensitive to changes in infection number. However, the
193 variance of the expected mean fluctuated over time and was sensitive to epidemiological dynamics. This
194 variance was smallest at the onset of the epidemic when infection numbers were highest and biggest
195 around day 400 when infection number was the smallest. The variance of the expected mean was
196 inversely correlated with total infection number, but its magnitude also depended on the rate with
197 which the epidemic was increasing or decreasing over time (**Figure 4, Supplemental Figure 3**).

198 Surprisingly, complete Sabin 2 reversion does not guarantee stable transmission. The
199 simulations with observed transmission failure did not show a lack of evolutionary fitness: the simulated
200 viral populations in these simulations had infectiousness and shedding durations equivalent to or
201 exceeding that of WPV (**Supplemental Figure 2B-C**).

202 *Population-level immunity and hygiene are major constraints of cVDPV2 emergence*

203 We next utilized this model to simulate cVDPV2 emergence and understand risk. Our scenarios
204 included a point importation of an infant vaccinated with Sabin 2, and a mass vaccination campaign with
205 up to 80% coverage in children under five years of age. We explored scenarios with fecal oral doses
206 equal to, five times greater, and 10 times greater than Matlab (**Figure 5**). The fecal oral dose, combined

207 with the infection-specific, time-dependent viral shedding concentration per gram of stool (22),
208 determines the total exposure dose per infectious contact. cVDPV2 emergence was defined as an
209 outbreak significant enough to trigger a warning from passive routine surveillance efforts. However,
210 because surveillance is not currently simulated, we operationally define cVDPV2 emergence as a
211 simulation with sustained cVDPV2 transmission for at least three years.

212 We found zero risk of cVDPV2 emergence following a mass vaccination campaign (**Figure 5A**) or
213 point importation event (**Figure 5D**) in Matlab with its current fecal oral dose. However, cVDPV2
214 emergence is possible at higher fecal-oral doses. Under these conditions, cVDPV2 emergence risk
215 increases with time since vaccination, but is controlled within the community by higher vaccination
216 coverage. When the fecal-oral dose was five times that of Matlab ($1.8e-6$ grams per contact), all
217 vaccination campaigns and point importations immediately after vaccination cessation (year 0) had a
218 less than 0.05 chance of causing a cVDPV2 emergence (**Figure 5B**). Vaccination campaigns with less than
219 30% coverage in populations with more than three years of vaccination cessation had the highest risk of
220 cVDPV2 emergence, with an emergence rate between 20% and 30%. Following point importation,
221 cVDPV2 emergence risk rises from 0% immediately after cessation to 20% after five years of cessation
222 (**Figure 5E**).

223 When the fecal-oral dose was ten times that of Matlab ($2.5e-6$ grams per contact), high
224 vaccination coverage could not efficiently prevent cVDPV2 emergence (**Figure 5C**). Immediately after
225 vaccination cessation, simulations with high vaccination coverage (> 70% coverage) resulted in cVDPV2
226 emergence 40-50% of the time. All other scenarios had a greater than 60% chance of cVDPV2
227 emergence. This increases to a greater than 80% chance following a vaccination campaign with less than
228 30% coverage in populations with more than three years of vaccination cessation. cVDPV2 emergence
229 risk following a point importation event increases sharply with time since vaccination (**Figure 5F**),
230 increasing from 5% immediately after cessation to 55% after five years of cessation.

231

232 **Discussion**

233 cVDPV2 outbreaks are serious public health dilemmas made possible by viral evolution and
234 exacerbated by epidemiological conditions. By unifying evolutionary and epidemiological theory into a
235 single framework, our model assesses cVDPV2 emergence risk in relation to changes in shedding
236 duration and infectiousness associated with vaccine reversion and the constraints to transmission
237 imposed by immunity, sanitation, and contact structure. To overcome the lack of direct transmission
238 measurements for Sabin 2 reversion intermediates, we generated genotype-to-phenotype maps for
239 shedding duration and viral infectiousness by relying on established molecular evolution and population
240 genetic theory.

241 Sabin 2 reversion can be viewed as an adaptive process where Sabin 2 must climb up a fitness
242 landscape to achieve the optimal, WPV-like phenotype. Within the poliovirus virology literature, Sabin 2
243 is commonly presented as a purely adaptive process where fixed mutations contribute positively to the
244 emergence of the WPV phenotype (24). However, it is unlikely that all fixed nonsynonymous mutations
245 are beneficial (25) and viruses must purge deleterious mutations to prevent Muller's Ratchet from
246 causing an irreversible decline in viral fitness (26, 27). Muller's ratchet can be avoided by engaging in
247 intra-species or inter-species recombination with Enterovirus C viruses (28) and by altering the
248 distribution of fitness effects (DOFE) for fixed mutations (29, 30). The latter is based on Fisher's
249 Geometric Model (FGM) of adaptive evolution, which predicts that mutations with large-phenotypic
250 effects are unlikely to fixate the closer an organism is to its fitness optimum. Our model incorporates
251 FGM by attributing large phenotypic effects to the gatekeeper mutations and specifying
252 nonsynonymous mutation rates so that early adaptive evolution is dominated by deleterious
253 nonsynonymous mutations while long-term evolution is dominated by neutral ones.

254 Interestingly, we failed to identify a deleterious cost associated with nonsynonymous mutations
255 and shedding duration but did identify one associated with nonsynonymous mutations and infectivity.
256 This finding suggests that there are differences between intra-host and inter-host selection. This could
257 reflect strong purifying selection induced by the highly competitive intra-host survival dynamics due to
258 high viral titers. Conversely, the deleterious cost associated with infectiousness could result from the
259 genetic drift induced by the severe sampling of viral genotypes during person-to-person transmission
260 (25, 31). Strong genetic drift could weaken the efficacy of purifying selection in removing deleterious
261 mutations associated with inter-host transmission, but more work is needed to assess differences in
262 inter- and intra-host selection. The phenotypes we modeled are the consolidation of multiple factors
263 such as cell invasion, replication, immune evasion, and environmental survival. These subfactors likely
264 contribute to both shedding duration and infectiousness, but our ability to map molecular evolution to
265 these subfactors remains limited.

266 At its core, cVDPV2 emergence is an evolutionary and epidemiological problem that requires a
267 combined approach to properly assess how the two interact. From an evolutionary perspective, the
268 availability of susceptible hosts and the distribution of transmissions dictates the strength of genetic
269 drift. Once the gatekeeper mutations are fixed, the phenotypic stability of the viral population is
270 maintained as a mutation-selection-drift balance and the range of phenotypic values explored by the
271 viral population is determined by the total number of infected individuals in the population. From an
272 epidemiological perspective, Sabin 2 reversion causes infectiousness and shedding duration to rapidly
273 increase within the first 200 days of vaccination and allow more individuals to become infected. Despite
274 the emergence of WPV-like viruses in our simulations, complete genetic reversion of Sabin 2 does not
275 guarantee a cVDPV2 outbreak. Whether these viruses cause a cVDPV2 outbreak requiring public health
276 intervention depends on population-level immunity and the average viral exposure dose per infectious
277 contact (4, 6, 22, 32).

278 The current strategies for controlling cVDPV2 involve implementing aggressive mOPV2 SIA
279 activities in outbreak response zones and neighboring regions, intensifying routine immunization in
280 high-risk areas with inactivated polio vaccine (IPV), ensuring a sufficient supply of Sabin 2 OPV for future
281 eradication strategies, and identifying high cVDPV2 outbreak risk zones (33). Our work clearly shows
282 that even regions with historically high vaccination rates are prone to cVDPV2 outbreaks if sanitation is
283 poor. Evaluations of high cVDPV2 outbreak risk regions should include sanitation assessments and utilize
284 tools designed to measure fecal contamination for other fecal-oral pathogens such as *E. coli* (34). Prior
285 to mass immunization with OPV2, sanitation assessments should be made to assess the risk of a cVDPV2
286 outbreak in both the targeted intervention zone and in the surrounding regions. These assessments will
287 be useful for resource allocation and for determining the minimum coverage needed to prevent future
288 cVDPV2 outbreaks. Regions with poor sanitation will require aggressive, high-coverage SIA vaccination
289 campaigns to prevent seeding future cVDPV2 outbreaks.

290 Sanitation assessments will also help public health officials determine whether additional WASH
291 (water, sanitation, and hygiene) interventions are needed to supplement ongoing vaccination activity.
292 Our study reconfirms that there are sanitation regimes defined by high fecal oral doses that is
293 guaranteed to seed future cVDPV2 outbreaks (22), regardless of vaccination coverage. Although long-
294 term investments in infrastructure are prohibitively expensive, relatively simple measures such as the
295 installation of sanitary latrines and drinking water tubewells have been effective at reducing fecal
296 contamination in Matlab, Bangladesh (35). Optimistically, short-term sanitation interventions may be
297 effective if implemented similarly to an emergency response campaign (36), especially if they are
298 targeted at vaccine recipients and their immediate household community members (21). These targeted,
299 short-term sanitation interventions could alleviate some of the challenges associated with non-
300 compliance, long-term adherence failure, and poor implementation that reduce the efficacy of standard
301 WASH interventions (37, 38).

302 Our model lays the foundations for integrating population genetic theory and epidemiology to
303 study the evolutionary epidemiology dynamics of rapidly evolving infectious diseases. The success of our
304 framework hinges on an understanding of a pathogen's evolutionary trajectory as well as the initial and
305 ending phenotypic states. We anticipate our model will be extended to the novel OPV2 (nOPV2)
306 candidates (39) as more about their clinical phenotypes and molecular evolution are known. Depending
307 on how attenuated and evolutionarily stable the novel OPV2 candidates are relative to Sabin 2, mass
308 nOPV2 vaccination may reduce the need to also control sanitation levels. We also anticipate our model
309 will be useful for assessing the risks associated with the live-attenuated varicella zoster vaccines, which
310 also shows strong evidence of attenuation reversion conferred by a commonly accessed evolutionary
311 pathway (40).

312 **Materials and Methods**

313 **Sequencing Data**

314 We downloaded fasta files for the VP1 segments and whole genome sequences of Sabin 2 and
315 Sabin 2 derived genomes from Genbank. These samples were collected across 102 studies performed in
316 countries including Egypt, Madagascar, China, Nigeria, the United States, Israel, Switzerland, and the
317 Democratic Republic of Congo. Multiple sequence alignments were first generated using MUSCLE
318 (v3.8.31) (41). Sequences were compared to a known Sabin 2 sample (accession ID: AY184220) to
319 identify and remove insertions. Sequences with long internal gaps (>15 bases) and coverage < 30%
320 (percentage of called bases) were discarded. Coding sequence alignments from the whole genome
321 sequences were generated for each of the poliovirus coding regions by generating multiple sequence
322 alignments for each of the 15 translated protein coding sequences of the poliovirus genome. These
323 alignments were further filtered to remove samples with < 90% coverage.

324 A total of 177 whole genome sequences and 1,643 VP1 sequences were retained for analysis.
325 Samples were classified as Sabin 2, Sabin-Like, VDPV (vaccine-derived poliovirus), iVDPV
326 (immunodeficiency-related vaccine-derived poliovirus), cVDPV2 based on their original study
327 classifications. Viruses that displayed <1% VP1 nucleotide sequence difference from the parental Sabin 2
328 genome were classified as Sabin-lik2 and those with 1-15% nucleotide sequence difference were
329 classified as VDPV. VDVPVs isolated from immunodeficient individuals were classified as iVDPV while
330 samples with evidence of having originated from prior transmission are classified as cVDPV2. The whole
331 genome sample set also included the Lansing and MEF-1 laboratory strains as well as several engineered
332 Lansing strain derivatives. Accession numbers, classifications, and study origin for each sample are in
333 **Supplemental File 1** and **Supplemental File 2**. FASTA files for the aligned VP1 and whole genome coding
334 sequences are available on the **Github repository**.

335 Coding sequence alignments were used to generate a phylogenetic tree using RAxML (v8.2.10)
336 with a general time reversible CAT (GTRCAT) model (42). Estimates of nonsynonymous and synonymous
337 mutation counts and dN/dS were based off the RAxML generated phylogenetic tree. Estimates of
338 nonsynonymous and synonymous mutation counts from the VP1 sequences were counted directly from
339 the sequence data. Nonsynonymous and synonymous mutation counts for codons with multiple
340 mutations were averaged across all possible, unweighted evolutionary paths.

341 **Model Description**

342 *Defining Genotypes*

343 Genotypes are defined relative to the Sabin-2 genome and defined by the reversion state of
344 three gatekeeper mutations (A481G, U2909C, and U398C), and the number of newly derived
345 nonsynonymous and synonymous mutations in the rest of the genome. The Sabin-2 genome is defined
346 as an array with 6 different mutation classes:

$$G_{S_2} = [0, 0, 0, 0, 0, 0]$$

347 The first three are Boolean flags that indicate the allelic states of A481G, U2909C, and U398C (0 =
348 unreverted, 1 = reverted). The last three elements represent the total number of deleterious
349 nonsynonymous, neutral nonsynonymous, and synonymous mutations present in the genome. The
350 counts in the latter categories exclude the three gatekeeper mutations. Splitting nonsynonymous
351 mutations into neutral and deleterious simplifies the true distribution of fitness effects and was
352 necessary to reconcile phenotypic and molecular evolution (**SI Appendix**). These genotypes represent
353 the consensus sequence of fixed variants within vaccinated and infected individuals.

354 For evolved poliovirus strains, we use the notation:

$$G_{i,j,k,nonsyn_{del},nonsyn_{neutral},syn}$$

355
356 where $i, j,$ and k are replaced with the allelic states of A481G, U2909C, and U398C. $nonsyn_{neutral},$
357 $nonsyn_{del},$ and syn are replaced with their respective counts or replaced with X if these mutation
358 classes are irrelevant. For example, $G_{0,0,0,0,0,0}$ is equivalent to the unmutated Sabin-2 vaccine strain (G_{S_2})
359 and $G_{1,1,1,10,2,15}$ is a genotype where all three gatekeeper mutations have reverted and where 10
360 deleterious nonsynonymous, 2 neutral nonsynonymous, and 15 synonymous mutations have
361 accumulated.

362 *Genomic evolution: Modeling Sabin 2 molecular evolution*

363 Genomic evolution is modeled using intra-host substitution rates (λ), the fixation of newly
364 derived mutations within the host, for each mutation class ($\lambda_{A481G}, \lambda_{U2909C}, \lambda_{U398C}, \lambda_{syn},$
365 $\lambda_{nonsyn_{del}}, \lambda_{nonsyn_{neutral}}$). This substitution rate reflects the true de novo mutation rate, genetic drift,

366 and selection within the host. This simplification allows us to use a single consensus genome to
367 represent the fixed mutations present in the intra-host viral population. Each mutation class (the three
368 gatekeeper mutations, synonymous mutations, deleterious nonsynonymous mutations, and neutral
369 nonsynonymous mutations) is associated with a substitution rate that describes its expected fixation
370 time (**Supplemental File 3**).

371 To accommodate the effects of intra-host competition and recombination, deleterious
372 nonsynonymous mutation accumulation also depends on a recombination-like mechanism with rate
373 $\lambda_{recombination}$ that purges deleterious mutations from the genome (26, 28, 43). Intra-host substitution
374 rates for the gatekeeper mutations were used as described in (10) while λ_{syn} ,
375 $\lambda_{nonsyn,del}$, $\lambda_{nonsyn,neutral}$, and $\lambda_{recombination}$ were calibrated to the whole genome sequences and
376 VP1 segments downloaded from Genbank. Only confirmed Sabin 2, Sabin-Like, VDPV, and cVDPV
377 samples were used for calibration. All other samples were excluded from calibration. Calibration details
378 are provided in the **SI Appendix**.

379 Upon vaccination with Sabin 2, fixation times for all mutation classes are calculated by drawing
380 from exponential distributions whose rate parameters are defined by the substitution rate of each
381 mutation class. For the three gatekeeper mutations, these fixation times determine the time to
382 reversion. For nonsynonymous and synonymous mutations, these fixation times determine the time to
383 the next substitution event. To prevent Mueller's Ratchet from resulting in infinite deleterious mutation
384 load, we also draw a time to the next "recombination" event from an exponential distribution defined
385 by $\lambda_{recombination}$. During each "recombination" event, the model draws a random number from a
386 discrete, uniform distribution ranging from zero to $n_{nonsyn,deleterious}$, the number of deleterious
387 nonsynonymous mutations in the genome, to determine the number of deleterious mutations to
388 remove. Conceptually, this represents purifying selection within the host and allows us to accommodate

389 the assumed increase in purifying selection as Sabin 2 reverts to cVDPV2. Pseudocode is provided in
390 ***Supplemental Figure 4.***

391

392 *Genotype to Phenotype: Mapping molecular genetics to shedding duration and infectiousness*

393 A core assumption of our model is that each of the three gatekeeper mutations contributes to
394 the final, WPV phenotype proportional to their relative substitution rates. This assumption is based in
395 part on evolutionary fitness landscape and adaptation theory, which posits that beneficial mutations of
396 large effect are more likely to be fixed early on when an organism is far the optimal fitness peak on a
397 simple, non-rugged fitness landscape (29, 44). By definition, attenuated Sabin 2 vaccine strains are far
398 from the optimal fitness peak for human infection and genetic reversion is the process of climbing the
399 fitness landscape to reach the optimal, WPV-like phenotype. Because of their fast substitution rate, we
400 attribute the bulk of phenotypic change to A481G, followed by U2909C, and to a lesser extent U398C.
401 The ranked ordering of phenotypic effect in our model is supported in the literature. A481G and U2909C
402 are consistently identified as the primary molecular determinants of reversion in *in vitro* and *in vivo*
403 studies (11–16). U398C is only occasionally identified by these studies but its recurrent fixation within
404 the first few months of transmission (9, 10) suggest its adaptive benefit may be too small to be assessed
405 in laboratory-based assays relative to A481G and U2909C.

406 Two epidemiologically relevant phenotypes were calculated for each infection based on its
407 corresponding genotype: 1) shedding duration and 2) infectiousness. Both shedding duration and
408 infectiousness are based on a previously described poliovirus dose-response model (22). Conceptually,
409 the shedding duration is analogous to intra-host selection and infectiousness is analogous to inter-host
410 selection. Details regarding model calibration are deferred to the **SI Appendix**.

411 We assume shedding duration follows a log-normal survival distribution with the form:

$$P(\text{shedding at } t \mid N_{ab_{pre}}; \text{infected at } t = 0) \quad (1)$$

$$= \frac{1}{2} \left(1 - \operatorname{erf} \left(\frac{\ln(t) - (M_g - \log(\delta) \log_2(N_{ab_{pre}}))}{\sqrt{2} \ln(S_g)} \right) \right)$$

412 where $N_{ab_{pre}}$ is the pre-infection OPV-equivalent antibody titer (22). For each genotype, M_g and S_g are
 413 genome-specific parameters that influence the average shedding duration and its standard deviation.
 414 The mean of this log-normal distribution is defined by $M_g - \log(\delta) \log_2(N_{ab_{pre}})$ and its standard
 415 deviation defined by S_g .

$$M_g = \log(\mu_{S_2}) + w_{shedding,g} \quad (2)$$

416

$$S_g = \sigma \sqrt{|1 + w_{shedding,g}|} \quad (3)$$

417

$$w_{shedding,g} = 0 + s_{dur,A481G} * G_{A481G} + s_{dur,U2909C} * G_{U2909C} + s_{dur,U398C} * G_{U398C} \quad (4)$$

$$+ s_{dur,nonsyn_{del}} * n_{nonsyn_{del}}$$

418

419 where μ_{S_2} is the average shedding duration of a completely unevolved Sabin 2 virus (G_{S_2}) in
 420 immunologically naive individuals ($N_{ab_{pre}} = 1$), σ the standard deviation in shedding duration for G_{S_2} .
 421 $w_{shedding,g}$ defines the shedding duration fitness of a strain, G_{A481G} , G_{U2909C} , and G_{U398C} refer to the
 422 allelic status of the three gatekeeper mutations, and $s_{dur,A481G}$, $s_{dur,U2909C}$, $s_{dur,U398C}$ are selection
 423 coefficients that describe the change in shedding duration conferred by each of these mutations. Note
 424 that fitness is additive but in log space.

425 Upon infection or vaccination, we randomly draw a shedding duration from a lognormal
426 distribution with mean $M_g - \log(\delta) \log_2(N_{ab_{pre}})$ and standard deviation S_g . A core feature of our
427 shedding duration model is that new gatekeeper mutations arising within the host extends shedding
428 duration. If a new gatekeeper mutation is acquired, the shedding duration is extended:

$$Duration = Duration_{initial} * e^{S_{gateway} + Norm(0,\sigma)\sqrt{S_{gateway}}} \quad (5)$$

429

$$S_{gateway} \in \{s_{dur,A481G}, s_{dur,U2909C}, s_{dur,U398C}\} \quad (6)$$

430

431 where $D_{initial}$ is the shedding duration before acquisition of the gatekeeper mutation and $S_{gateway}$ is
432 the shedding duration selection coefficient for the gatekeeper mutation. Note that $Duration_{initial}$ and
433 the increase in shedding duration, $e^{S_{gateway} + Norm(0,\sigma)\sqrt{S_{gateway}}}$, are log-normally distributed and that
434 multiplying two, independent log-normal distributions results in a log-normal distribution whose mean
435 and variance are the sum of the mean and variances of the original distributions. As a result, shedding
436 duration is the summation of multiple, genome-specific shedding durations whose weights are time-
437 dependent and depend on the fixation of A481G, U2909C, U398C and the accumulation of
438 nonsynonymous mutations.

439 Infectiousness is defined by a beta-Poisson model that assumes a single infectious unit is
440 sufficient to start an infection and that multiple infectious units contribute independently to the
441 probability of infection:

$$P(infection|dose, N_{ab}) = 1 - \left(1 + \frac{dose}{\beta_g}\right)^{-\alpha(N_{ab})^{-\gamma}} \quad (7)$$

442

443 where α and β_g are parameters for a beta-Poisson function, dose is the viral exposure dose, and γ
444 captures the reduction in shedding probability with increasing immunity. Altering the β parameter
445 shifts the beta-poisson function along the x-axis (dose) and altering the α parameter changes its slope.
446 Differences in infectiousness between Sabin 2 strains and WPV can be modeled using the same α but
447 with modified β parameters (22). We interpret the β parameter as a measurement of strain infectivity
448 and define β_g as:

$$\beta_g = \frac{\beta}{(1 + S_{inf,A481G})^{G_{A481G}} (1 + S_{inf,U2909C})^{G_{U2909C}} (1 + S_{inf,U398C})^{G_{U398C}} (1 + S_{inf,nonsyn_{del}})^{n_{nonsyn_{del}}}} \quad (8)$$

449
450
451
452 where β is the strain infectivity parameter for Sabin 2 (22) (assuming no evolution), $S_{inf,A481G}$,
453 $S_{inf,U2909C}$, $S_{inf,U398C}$, $S_{inf,nonsyn_{del}}$ are selection coefficients denoting the change in infectiousness
454 conferred by each of the gatekeeper mutations, and $n_{nonsyn_{del}}$ are the number of nonsynonymous
455 mutations in the genome. Parameter estimates were obtained by comparing the CCID50 between Sabin
456 2 and WPV (**SI Appendix**). The inferred selection coefficients for the three gatekeeper mutations are
457 positive (increases infectiousness) while the selection coefficient for deleterious nonsynonymous
458 mutations was negative (decreases infectiousness). Infectiousness is calculated only at the onset of
459 either vaccination or infection.

460

461 **Acknowledgements**

462 We acknowledge all members of the Institute for Disease Modeling, Global Good, and the Bill and
463 Melinda Gates Foundation for their useful discussion and input. We also acknowledge Adam Luring and
464 Andrew Valesano for early manuscript edits and comments.

465 **Funding**

466 Funding was provided by Bill and Melinda Gates through the Global Good Fund. Funders had no role in
467 the study design, data collection, analysis, interpretation, or writing of the manuscript. The
468 corresponding author had full access to all the data in our study and had final responsibility for the
469 decision to submit for publication.

470 **Data Availability**

471 Data and code will be made publicly available at
472 https://github.com/InstituteforDiseaseModeling/MultiscaleModeling/tree/evo_epistasis upon
473 publication.

474 **Declaration of Interests**

475 The authors declare no competing interests during the study. WW, JG, and MF were employed by the
476 funders through the Bill and Melinda Gates Foundation after study completion.

477 **References**

- 478 1. F. Khan, *et al.*, Progress Toward Polio Eradication — Worldwide, January 2016–March 2018.
479 *MMWR Morb Mortal Wkly Rep* 2019, 524–528 (2018).
- 480 2. A. S. Bandyopadhyay, J. Garon, K. Seib, W. A. Orenstein, Polio vaccination: past, present and
481 future. *Future Microbiol.* **10**, 791–808 (2015).
- 482 3. H. E. Jenkins, *et al.*, Implications of a Circulating Vaccine-Derived Poliovirus in Nigeria. *N. Engl. J.*

- 483 *Med.* **362**, 2360–2369 (2010).
- 484 4. J. Jorba, *et al.*, Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, January 2018–
485 June 2019. *Morb. Mortal. Wkly. Rep.*, 1024–1028 (2019).
- 486 5. M. Alleman, *et al.*, Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide July 2019–
487 February 2020. *MMWR Morb Mortal Wkly Re*, 89–495 (2020).
- 488 6. G. R. Macklin, *et al.*, Evolving epidemiology of poliovirus serotype 2 following withdrawal of the
489 type 2 oral poliovirus vaccine. *Science (80-.)*, eaba1238 (2020).
- 490 7. J. W. Almond, The attenuation of poliovirus neurovirulence. *Annu. Rev. Microbiol.* **41**, 153–180
491 (1987).
- 492 8. A. B. Sabin, L. R. Boulger, History of Sabin attenuated poliovirus oral live vaccine strains. *J. Biol.*
493 *Stand.* **1**, 115–118 (1973).
- 494 9. A. Stern, *et al.*, The Evolutionary Pathway to Virulence of an RNA Virus. *Cell* **169**, 35-46.e19
495 (2017).
- 496 10. M. Famulare, *et al.*, Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like
497 Poliovirus Isolates in Nigeria. *J. Virol.* **90**, 317–331 (2015).
- 498 11. O. M. Kew, R. W. Sutter, E. M. de Gourville, W. R. Dowdle, M. A. Pallansch, Vaccine-derived
499 polioviruses and the endgame strategy for global polio eradication. *Annu. Rev. Microbiol.* **59**,
500 587–635 (2005).
- 501 12. R. J Duintjer Tebbens, *et al.*, Oral Poliovirus Vaccine Evolution and Insights Relevant to Modeling
502 the Risks of Circulating Vaccine-Derived Polioviruses (cVDPVs). *Risk Anal.* **23** (2013).
- 503 13. A. R. Muzychenko, *et al.*, Coupled mutations in the 5'-untranslated region of the Sabin poliovirus

- 504 strains during in vivo passages: structural and functional implications. *Virus Res.* **21**, 111–122
505 (1991).
- 506 14. K. M. S. de M. Cassemiro, *et al.*, Molecular and Phenotypic Characterization of a Highly Evolved
507 Type 2 Vaccine-Derived Poliovirus Isolated from Seawater in Brazil, 2014. *PLoS One* **11**,
508 e0152251–e0152251 (2016).
- 509 15. E. A. Simoes, P. Sarnow, An RNA hairpin at the extreme 5' end of the poliovirus RNA
510 genome modulates viral translation in human cells. *J. Virol.* **65**, 913 LP – 921 (1991).
- 511 16. R. B. Ren, E. G. Moss, V. R. Racaniello, Identification of two determinants that attenuate vaccine-
512 related type 2 poliovirus. *J. Virol.* **65**, 1377–1382 (1991).
- 513 17. H. Asghar, *et al.*, Environmental Surveillance for Polioviruses in the Global Polio Eradication
514 Initiative. *J. Infect. Dis.* **210**, S294–S303 (2014).
- 515 18. R. Abraham, P. Minor, G. Dunn, J. F. Modlin, P. L. Ogra, Shedding of Virulent Poliovirus Revertants
516 during Immunization with Oral Poliovirus Vaccine after Prior Immunization with Inactivated Polio
517 Vaccine. *J. Infect. Dis.* **168**, 1105–1109 (1993).
- 518 19. I. M. Blake, *et al.*, Type 2 Poliovirus Detection after Global Withdrawal of Trivalent Oral Vaccine.
519 *N. Engl. J. Med.* **379**, 834–845 (2018).
- 520 20. M. Taniuchi, *et al.*, Community transmission of type 2 poliovirus after cessation of trivalent oral
521 polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study. *Lancet.*
522 *Infect. Dis.* **17**, 1069–1079 (2017).
- 523 21. M. Famulare, *et al.*, Community structure mediates Sabin 2 polio vaccine virus transmission.
524 *medRxiv*, 2020.07.01.20144501 (2020).

- 525 22. M. Famulare, C. Selinger, K. A. McCarthy, P. A. Eckhoff, G. Chabot-Couture, Assessing the stability
526 of polio eradication after the withdrawal of oral polio vaccine. *PLOS Biol.* **16**, e2002468 (2018).
- 527 23. S. Wassilak, *et al.*, Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and
528 widespread circulation in an underimmunized population. *J. Infect. Dis.* **203**, 898–909 (2011).
- 529 24. K. M. Thompson, R. J. Duintjer Tebbens, Modeling the dynamics of oral poliovirus vaccine
530 cessation. *J. Infect. Dis.* **210 Suppl**, S475-84 (2014).
- 531 25. A. L. Hughes, Near-Neutrality: the Leading Edge of the Neutral Theory of Molecular Evolution.
532 *Ann N Y Acad Sci* **1133**, 162–179 (2008).
- 533 26. L. Chao, Fitness of RNA virus decreased by Muller’s ratchet. *Nature* **348**, 454–455 (1990).
- 534 27. T. Leitner, The Puzzle of HIV Neutral and Selective Evolution. *Mol. Biol. Evol.* **35**, 1355–1358
535 (2018).
- 536 28. Y. Xiao, *et al.*, RNA Recombination Enhances Adaptability and Is Required for Virus Spread and
537 Virulence. *Cell Host Microbe* **19**, 493–503 (2016).
- 538 29. O. Tenailon, The Utility of Fisher’s Geometric Model in Evolutionary Genetics. *Annu. Rev. Ecol.*
539 *Evol. Syst.* **45**, 179–201 (2014).
- 540 30. D. L. Hartl, C. H. Taubes, Towards a theory of evolutionary adaptation. *Genetica* **102–103**, 525–
541 533 (1998).
- 542 31. J. T. McCrone, *et al.*, Stochastic processes constrain the within and between host evolution of
543 influenza virus. *Elife* **7**, e35962 (2018).
- 544 32. K. A. McCarthy, G. Chabot-Couture, M. Famulare, H. M. Lyons, L. D. Mercer, The risk of type 2
545 oral polio vaccine use in post-cessation outbreak response. *BMC Med.* **15**, 175 (2017).

- 546 33. Geneva: World Health Organization, “Strategy for the Response to Type 2 Circulating Vaccine-
547 Derived Poliovirus 2020–2021: An addendum to the Polio Endgame Strategy 2019-2023” (2020).
- 548 34. Y. Wang, *et al.*, Multipathway Quantitative Assessment of Exposure to Fecal Contamination for
549 Young Children in Low-Income Urban Environments in Accra, Ghana: The SaniPath Analytical
550 Approach. *Am. J. Trop. Med. Hyg.* **97**, 1009–1019 (2017).
- 551 35. K. Zaman, *et al.*, Can cholera ‘hotspots’ be converted to cholera ‘coldspots’ in cholera endemic
552 countries? The Matlab, Bangladesh experience. *Int. J. Infect. Dis.* **95**, 28–31 (2020).
- 553 36. T. Yates, J. Allen, M. L. Joseph, D. Lantagne, “Short-term WASH interventions in emergency
554 responses in low- and middle-income countries” (2017).
- 555 37. A. Ramesh, K. Blanchet, J. H. J. Ensink, B. Roberts, Evidence on the Effectiveness of Water,
556 Sanitation, and Hygiene (WASH) Interventions on Health Outcomes in Humanitarian Crises: A
557 Systematic Review. *PLoS One* **10**, e0124688–e0124688 (2015).
- 558 38. M. Wolfe, M. Kaur, T. Yates, M. Woodin, D. Lantagne, A Systematic Review and Meta-Analysis of
559 the Association between Water, Sanitation, and Hygiene Exposures and Cholera in Case–Control
560 Studies. *Am. J. Trop. Med. Hyg.* **99**, 534–545 (2018).
- 561 39. P. Van Damme, *et al.*, The safety and immunogenicity of two novel live attenuated monovalent
562 (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1
563 study. *Lancet* **394**, 148–158 (2019).
- 564 40. J. Breuer, Molecular Genetic Insights Into Varicella Zoster Virus (VZV), the vOka Vaccine Strain,
565 and the Pathogenesis of Latency and Reactivation. *J. Infect. Dis.* **218**, S75–S80 (2018).
- 566 41. R. C. Edgar, MUSCLE: a multiple sequence alignment method with reduced time and space
567 complexity. *BMC Bioinformatics* **5**, 113 (2004).

- 568 42. A. Stamatakis, RAxML version 8: a tool for phylogenetic analysis and post-analysis of large
569 phylogenies. *Bioinformatics* **30**, 1312–1313 (2014).
- 570 43. M. Bessaud, M.-L. Joffret, B. Blondel, F. Delpyroux, Exchanges of genomic domains between
571 poliovirus and other cocirculating species C enteroviruses reveal a high degree of plasticity. *Sci.*
572 *Rep.* **6**, 38831 (2016).
- 573 44. E. Svensson, R. Calsbeek, *The Adaptive Landscape in Evolutionary Biology* (OUP Oxford, 2012).

574

575


576

577

578


579

580




581

582 **Figure 1 Sabin 2 transmission and reversion schematic A)** Multiscale epidemiology model. Individuals
583 are organized into a series of nested, demographic scales defined by households, *baris*/neighborhoods,
584 and villages that together define the greater region. The *bari* is an intergenerational living arrangement
585 of closely related individuals specific to Matlab, the study population the epidemiology model was
586 calibrated to. Conceptually, it is analogous to a neighborhood. Infectious contacts occur at different
587 rates to individuals in each of these demographic scales. During each infectious contact, infected
588 individuals transmit a viral dose that depends on their individual viral shedding concentration and the
589 average fecal oral dose per contact in the population. **B)** Sabin 2 reversion model. Sabin 2 evolution is
590 modeled as a population of competing viral lineages whose average phenotypic end state distribution is
591 identical to that of WPV. Reversion is driven by the acquisition of three gatekeeper mutations (A481G,
592 U2909C, U398C) and the acquisition of deleterious mutations introduced through mutation and purged
593 through selection.
594




596 **Figure 2 Molecular evolution.** **A)** Phylogenetic tree based on the nonsynonymous mutations from the
597 177 whole genome sequences used to calibrate our model. Samples were categorized as Sabin 2, Sabin-
598 Like, vaccine-derived poliovirus isolated from immunocompromised individuals (iVDPV), vaccine-derived
599 poliovirus (VDPV), and cVDPV2. The other category includes the Lansing and MEF-1 laboratory strains as
600 well as several engineered strains derived from the Lansing strain. Samples classified as iVDPV or
601 “other” were excluded from model calibration. **B)** Simulated genome-wide nonsynonymous mutation
602 accumulation over time (*orange*) compared against those observed in the Sabin 2, Sabin-Like, VDPV, and
603 cVDPV2 whole genome sequences. **C)** Simulated (*pink*) VP1 mutation (synonymous and
604 nonsynonymous) accumulation over time compared against the mutation counts observed in 1,643 VP1
605 segments. **D)** The ratio of nonsynonymous and synonymous mutations throughout the genome over
606 time. **E)** Simulated genome-wide nonsynonymous counts partitioned into deleterious (*brown*) and
607 neutral (*grey*). Across all figures, the solid line is the mean simulation outcome and the shaded area
608 marks the boundaries of the middle 95%. Empirical data is represented by points and colored according
609 to the legend in panel **A**. Time was calculated by dividing the number of synonymous mutations per
610 sample by the synonymous substitution rate ($3.16E-05$ substitutions/bp/day). The insets in **B,C,** and **E**
611 are close ups of the first year of evolution to better show short-term evolution dynamics.
612



613

614 **Figure 3 Phenotypic Evolution A)** Cumulative density reversion probability functions for the three
615 gatekeeper mutations. The solid line is the mean and the shading the 95% confidence interval. **B)**
616 Shedding duration profile of immunologically naïve individuals infected with Sabin 2, WPV/cVDPV2, and
617 three different intermediate viral genotypes. The dotted lines are the shedding durations of the initial
618 viral genotype assuming no further reversion or evolution. The solid line are the shedding durations of
619 each viral genotype where the reversion of new gatekeeper mutations extends the current shedding
620 duration. Nonsynonymous mutations have no discernable phenotypic effect with regards to shedding
621 duration. **C and D)** Viral infectiousness. Each curve shows strain-specific probability of infection given a
622 single CCID50 dose plotted against immunity. Panel **C** shows infectiousness following the acquisition of
623 each of the three gatekeeper mutations. Panel **D** emphasizes the role of deleterious nonsynonymous


624 mutation and shows the infection probability of different viral genotypes with all gatekeeper mutations
625 and deleterious nonsynonymous mutations count ranging from zero to 35.
626



627
628 **Figure 4 Evo-epidemiological dynamics** following a mass vaccination campaign targeting 10% of children
629 under five, five years post-vaccination cessation in Matlab, Bangladesh. Simulations assume 10x the
630 fecal oral dose in Matlab to ensure stable transmission and conditioned on stable, endemic transmission
631 for at least three years. **A)** Total number of infected individuals over time. Solid line indicates the mean
632 and the shading the boundaries of the middle 95% from 200 simulations **B)** Longitudinal immune

633 profiles for individuals with low immunity (*red*, antibody titer < 8), intermediate immunity (*light blue*,
634 antibody titer > 8 and < 256), and high immunity (*dark blue*, antibody titer > 256). **C**) Shedding duration
635 evolution in naïve individuals over time. **D**) Viral infectiousness evolution over time. For panels **B-D**, the
636 solid line denotes the simulated average and the boundaries the 95% confidence interval around the
637 mean. For panels **C** and **D**, the dashed black line indicates the average WPV phenotype.


638



639

640 **Figure 5 cVDPV2 outbreak risk.** cVDPV2 emergence after a mOPV2 vaccination campaign (**A-C**) or
641 importation of a single infant immunized with Sabin 2 (**D-F**) occurring after up to five years of
642 vaccination cessation with fecal-oral doses equivalent to (**A/D**), five times greater (**B/E**), and 10 times
643 greater (**C/F**) than that inferred for Matlab during an mOPV2 clinical trial.

644




645

646 **Supplemental Figure 1** dN/dS ratios for Sabin 2-like, cVDPV2, WPV, and iVDPVs.

647

648

649



650

651 **Supplemental Figure 2 Simulated evolutionary and epidemiology dynamics** following a mass

652 vaccination campaign targeting 10% of children under five, five years post-vaccination cessation in


653 Matlab, Bangladesh, conditioned on epidemic extinction within the first three years of transmission. **A)**

654 Total number of infected individuals over time **B)** Infectiousness represented as the probability of

655 infecting an immunologically naïve individual given single CCID50 unit dose. **C)** Shedding duration in

656 immunologically naïve individuals. Each line represents a different simulation outcome.

657



658

659 **Supplemental Figure 3** The variance of the expected mean (*black*) for shedding duration (**A**) and
660 infectiousness (**B**) compared against infection count (*orange*). The solid orange line is the mean and
661 shading the boundaries of the middle 95 percentile from 200 simulations and identical to **Figure 4A**.

Algorithm 1: Sabin 2 Intra-Host Molecular evolution

Initialization:

Step 1: Set reversion times for unreverted gateway mutations
for *mutation* in *A481G, U2909C, U398C* **do**
 if not reverted **then**
 | Draw reversion time, $t_{reversion_mutation}$, from Exponential($\lambda_{mutation}$)
 end
end

Step 2: Set substitution times for non-gateway mutations
for *mutation* in *nonsyn_{del}, nonsyn_{neutral}, syn* **do**
 | Draw substitution time, $t_{substitution_mutation}$, from Exponential($\lambda_{mutation}$)
end

Step 3: Set recombination time
 Draw recombination time, t_{recomb} , from Exponential(λ_{recomb})

Intra-host Evolution:

while $t_{infection} < t_{shed}$ **do**
 Step 1: Check if unreverted gateway mutations will revert
 for *mutation* in *A481G, U2909C, U398C* **do**
 if $t_{infection} = t_{reversion_mutation}$ **then**
 | Revert *mutation*
 end
 end
 Step 2: Check if new non-gateway mutations are fixed
 for *mutation* in *nonsyn_{del}, nonsyn_{neutral}, syn* **do**
 if $t_{infection} = t_{reversion_mutation}$ **then**
 | Increase mutation count, $n_{mutation}$, by 1
 | Draw a new $t_{mutation}$ from Exponential($\lambda_{mutation}$)
 end
 end
 Step 3: Check if deleterious nonsynonymous mutations are purged
 if $t_{infection} = t_{recomb}$ **then**
 | Draw X from Uniform(0, n_{nonsyn_del})
 | Subtract X from the deleterious nonsynonymous mutation count, n_{nonsyn_del}
 | Draw a new t_{recomb} from Exponential(λ_{recomb})
 end
end

664

Genotype	Proportion	Expected Shedding Duration
Sabin 2 (no reversions)	0.076 (0.059, 0.093)	14.39 (14.08, 14.69)
A481G only	0.186 (0.162, 0.211)	25.46 (24.71, 26.24)
U2909C only	0.024 (0.014, 0.034)	20.39 (19.85, 20.92)
U398C only	0.01 (0.004, 0.016)	18.98 (18.52, 19.47)
A481G + U398C	0.075 (0.059, 0.091)	33.53 (32.46, 34.62)
U398C + U2909C	0.005 (0.001, 0.01)	26.90 (26.10, 27.72)
A481G + U2909C	0.273 (0.247, 0.300)	36.08 (34.93, 37.26)
A481G + U2909C + U398C	0.352 (0.325, 0.382)	47.51 (45.93, 49.174)

665

666 **Supplemental Table 1** Final viral genotypes in primary vaccine recipients and the expected shedding
667 durations of individuals infected with these genotypes, assuming no further reversion. Bootstrapped
668 confidence interval for the mean were calculated from 1000 simulated primary vaccinations, repeated
669 1000 times. Shedding durations are reported in days. Sabin 2 in this table is defined as a viral genotype
670 with zero gatekeeper reversions.

671

672 **Supplemental File 1** Accession numbers and study origins of the whole genome sequences

673 **Supplemental File 2** Accession numbers and study origins of the VP1 segments

674